ALEXION PHARMACEUTICALS, INC. ALXN Income Statement

Alexion pharmaceuticals, inc. (ALXN)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Sep'09	Jun'09
Total revenues
5,295	4,991	4,735	4,499	4,340	4,131	3,912	3,744	3,612	3,551	3,472	3,412	3,252	3,084	2,953	2,821	2,704	2,604	2,458	2,304	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of sales:
Cost of sales (exclusive of amortization of purchased intangible assets)
420	394	377	372	368	374	422	488	476	454	377	291	268	258	247	230	222	233	225	222	210	174	175	166	166	168	149	140	133	126	121	112	102	93	84	77	69	64	56	49	0	0	0
Gain on intellectual property settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Change in contingent liability from intellectual property settlements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Total cost of sales
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-
Research and development
891	886	822	763	749	730	789	810	835	878	819	818	800	757	742	712	664	709	647	582	543	514	470	458	434	317	294	260	251	222	193	176	152	137	130	118	106	98	92	85	0	0	0
Selling, general and administrative
1,299	1,261	1,198	1,158	1,136	1,111	1,089	1,101	1,089	1,094	1,056	1,015	981	953	936	919	908	862	804	749	687	630	581	546	510	489	467	434	406	384	358	346	329	308	284	264	241	226	205	190	0	0	0
Research and Development Asset Acquired Other than Through Business Combination, Written-off
-	-	0	0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of purchased intangible assets
303	309	315	320	320	320	320	320	320	320	320	322	322	322	321	276	196	116	36	0	0	-	0	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Change in fair value of contingent consideration
46	11	12	36	35	116	120	70	90	41	36	73	54	35	49	38	37	64	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition-related costs
0	-	-	-	0	-	-	-	-	-	-	-	-	2	5	11	40	39	25	27	0	0	4	-1	-2	1	10	8	12	22	21	21	17	13	0	0	0	-	-	-	-	-	-
Restructuring expenses
2	12	11	21	29	25	32	94	86	104	99	28	25	3	13	19	36	42	45	38	22	15	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total costs and expenses
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of intangible assets
-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	12	36	36	36	33	26	0	0	-	0	-	-	-	0	-	-	-	-	-	-	-	-
Total operating expenses
-	-	2,735	2,674	-	3,487	3,155	3,200	2,452	2,469	2,448	2,375	2,271	2,158	2,068	1,977	1,882	1,834	1,634	1,443	1,294	1,191	1,097	1,044	983	845	772	730	697	656	600	543	499	459	426	394	359	325	298	276	0	0	0
Operating income
2,299	2,120	1,623	1,451	519	269	334	56	682	627	646	745	713	667	637	612	598	536	643	725	763	869	803	701	620	528	497	505	451	404	371	295	260	230	200	177	160	150	133	111	0	0	0
Other income and expense:
Investment (expense) income
52	100	-3	-20	2	65	125	123	120	18	15	16	13	10	9	6	6	8	8	9	8	8	7	6	5	3	2	2	2	1	1	1	1	1	2	2	1	1	1	0	0	0	0
Interest expense
83	77	80	87	94	98	98	99	99	98	98	97	96	96	95	91	71	47	25	5	2	3	3	3	4	4	4	5	6	7	6	4	2	0	0	0	0	0	0	0	0	0	0
Other income and (expense)
32	35	4	6	5	5	3	0	1	0	-1	-0	-3	-5	-5	-1	-0	0	1	-3	-2	-2	-2	-1	-0	-0	-0	-0	-0	-1	-2	-2	-2	-2	-2	-1	-1	-2	-1	-0	0	0	0
Debt exchange expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Income before income taxes
2,300	2,178	1,543	1,350	432	242	364	80	705	547	562	663	627	576	546	526	534	498	628	725	767	872	804	702	621	526	495	502	446	397	364	289	256	229	199	176	159	149	132	107	0	0	0
Income tax expense (benefit)
-73	-225	73	16	16	164	211	180	183	104	56	140	149	176	173	432	389	353	397	132	178	215	320	302	291	273	142	150	154	142	142	93	62	54	46	60	56	51	35	21	0	0	0
Net income
2,374	2,404	1,470	1,333	416	77	152	-100	522	443	506	522	477	399	372	94	145	144	231	592	588	657	484	400	330	252	352	351	291	254	222	195	193	175	153	115	102	97	97	86	0	0	0
Earnings per common share
Basic
2.52	4.00	2.09	2.05	2.63	-0.20	1.48	-2.05	1.12	0.13	0.35	0.74	0.76	0.41	0.42	0.54	0.41	0.19	-0.81	0.84	0.46	0.77	0.90	0.84	0.81	-0.10	0.48	0.49	0.42	0.43	0.48	0.19	0.24	0.26	0.36	0.19	0.15	0.02	0.16	0.12	0.24	0.31	0.20
Diluted
2.50	3.97	2.08	2.04	2.61	-0.18	1.47	-2.05	1.11	0.14	0.35	0.73	0.75	0.40	0.42	0.53	0.41	0.20	-0.81	0.83	0.45	0.76	0.88	0.83	0.79	-0.09	0.47	0.48	0.41	0.41	0.46	0.18	0.23	0.25	0.34	0.18	0.14	0.02	0.15	0.12	0.23	0.29	0.19
Shares used in computing earnings per common share
Basic
221	221	223	224	223	223	222	222	222	223	223	224	224	224	224	224	225	225	226	202	199	198	198	197	197	196	195	195	194	194	193	188	185	184	183	182	181	268	178	178	88	87	85
Diluted
222	223	224	225	225	227	224	222	223	224	225	225	226	226	226	226	227	230	226	204	202	203	201	201	201	200	199	199	199	201	201	197	194	193	192	191	190	281	186	185	92	90	90
Comprehensive income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-
Net Product Sales
Total revenues
5,294	4,990	4,734	4,497	4,339	4,130	3,911	3,743	3,610	3,549	3,470	3,410	3,250	3,081	2,951	2,819	2,702	2,602	2,501	2,391	2,267	2,234	2,076	1,921	1,779	1,551	1,429	1,323	1,228	1,134	1,041	951	862	783	711	649	589	540	487	438	0	0	0
Other Revenue
Total revenues
1	1	1	1	0	1	1	1	1	1	1	2	1	2	2	2	2	1	1	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-